Setogepram Solid-State Forms for Stability and Dissolution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for additional solid state forms of Setogepram, including solvated forms, to improve processing, handling, stability, and bioavailability, which are not adequately addressed by existing technologies.
Innovation Solution
The development of crystalline polymorphs and salts of Setogepram, particularly Setogepram sodium, with specific characterization by XRPD and 13C NMR, and processes for their preparation, including solvent removal and cooling steps, to obtain forms ST2 and ST3, which can be used in pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If new solid state forms of Setogepram are developed, then processing and handling characteristics are improved, but the complexity of the formulation process increases
Solution Approach 1:
The patent applies parameter changes by developing multiple solid state forms (polymorphs and salts) of Setogepram with different physical and chemical parameters. Each solid state form has distinct properties such as solubility, stability, and crystalline structure, allowing formulation scientists to select the most appropriate form for specific manufacturing and processing requirements. This resolves the contradiction by providing varied options that improve ease of manufacture without necessarily increasing process complexity, as each form is characterized and can be produced through established pharmaceutical techniques.
2Productivity
If different solid state forms are used, then dissolution profile and bioavailability are improved, but the number of materials to be evaluated increases
Solution Approach 1:
The patent utilizes parameter changes by creating solid state forms with modified physical properties that directly influence dissolution rate and bioavailability. By changing the crystalline structure, salt form, or solvate status of Setogepram, the formulation can be optimized for faster or more complete dissolution. This approach improves productivity in terms of therapeutic efficacy while the increased number of materials is systematically managed through characterization techniques and selection based on specific therapeutic goals.
Solution Approach 2:
The patent applies segmentation by dividing the single active pharmaceutical ingredient (Setogepram) into multiple distinct solid state forms, each with tailored properties. Rather than attempting to optimize one form for all applications, the invention segments the material into polymorphs, salts, and solvates that can be selectively used for different dosage forms, routes of administration, or patient populations, thereby improving dissolution and bioavailability for specific indications.
3Reliability
If solid state forms with improved stability are developed, then shelf-life is extended, but the characterization and validation process becomes more complex
Solution Approach 1:
The patent applies parameter changes by developing solid state forms with enhanced chemical stability through modifications in crystalline packing, salt selection, or solvate formation. These structural changes reduce the rate of degradation reactions and improve resistance to environmental factors such as moisture and light. The extended shelf-life achieved through these parameter changes is validated through systematic characterization using techniques such as X-ray diffraction, thermal analysis, and spectroscopy, which, while complex, provide comprehensive evidence of stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new solid state forms provide improved chemical stability, dissolution profile, and handling characteristics, enhancing the potential for better formulation and therapeutic efficacy in treating Alstrom Syndrome and Idiopathic pulmonary fibrosis.
Implementation Method 1
processes for preparation thereof, including solvent removal and cooling steps
Implementation Method 2
The development of crystalline polymorphs and salts of Setogepram, particularly Setogepram sodium
Data Source
Figure 1
Figure 2
Figure 3A
AI summary
The present disclosure encompasses solid state forms of Setogepram, in embodiments crystalline polymorphs or salts of Setogepram, particularly Setogepram sodium, processes for preparation thereof, and pharmaceutical compositions thereof.